Journal article
High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial
The Journal of infectious diseases, v 203(6), pp 756-764
15 Mar 2011
PMID: 21325137
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
(See the editorial commentary by Carr, on pages
751–2
.)
Background
. 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) exhibit antiviral activity against human immunodeficiency virus type 1 (HIV-1) in vitro and may modulate the immune response to HIV infection. Studies evaluating the antiviral activity of statins have yielded conflicting results.
Methods
. We conducted a randomized, double-blind, placebo-controlled crossover trial to investigate the effect of atorvastatin on HIV-1 RNA (primary objective) and cellular markers of immune activation (secondary objective). HIV-infected individuals not receiving antiretroviral therapy were randomized to receive either 8 weeks of atorvastatin (80 mg) or placebo daily. After a 4–6 week washout phase, participants switched treatment assignments. The study had 80% power to detect a 0.3 log
10
decrease in HIV-1 RNA level. Expression of CD38 and HLA-DR on CD4
+
and CD8
+
T cells was used to measure immune activation.
Results
. Of 24 randomized participants, 22 completed the study. Although HIV-1 RNA level was unaffected by the intervention (–0.13 log
10
copies/mL;
P
= .85), atorvastatin use resulted in reductions in circulating proportions of CD4
+
HLA-DR
+
(–2.5%;
P
= .02), CD8
+
HLA-DR
+
(–5%;
P
= .006), and CD8
+
HLA-DR
+
CD38
+
T cells (–3%;
P
= .03). Reductions in immune activation did not correlate with declines in serum levels of low-density lipoprotein cholesterol.
Conclusions
. Short-term use of atorvastatin was associated with modest but statistically significant reductions in the proportion of activated T lymphocytes.
Metrics
Details
- Title
- High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial
- Creators
- Anuradha Ganesan - Uniformed Services University of the Health SciencesNancy Crum-Cianflone - Uniformed Services University of the Health SciencesJeanette Higgins - Science Applications International CorporationJing Qin - Cancer Research And BiostatisticsCatherine Rehm - Clinical Research SectionJulia Metcalf - National Institute of Allergy and Infectious DiseasesCarolyn Brandt - Naval Medical Center San DiegoJean Vita - Naval Medical Research CenterCatherine F. Decker - Naval Medical Research CenterPeter Sklar - Drexel UniversityMary Bavaro - Naval Medical Center San DiegoSybil Tasker - Pharmaceutical Product DevelopmentDean Follmann - Cancer Research And BiostatisticsFrank Maldarelli - National Institutes of Health
- Publication Details
- The Journal of infectious diseases, v 203(6), pp 756-764
- Series
- Editor's Choice
- Publisher
- Oxford University Press
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Infectious Diseases (and HIV Medicine)
- Web of Science ID
- WOS:000287742700003
- Scopus ID
- 2-s2.0-79952341800
- Other Identifier
- 991019168092504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- Web of Science research areas
- Immunology
- Infectious Diseases
- Microbiology